Palisade Bio Statistics
Total Valuation
Palisade Bio has a market cap or net worth of $371.20 million. The enterprise value is $246.02 million.
| Market Cap | 371.20M |
| Enterprise Value | 246.02M |
Important Dates
The last earnings date was Monday, August 10, 2026, after market close.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Palisade Bio has 174.27 million shares outstanding. The number of shares has increased by 4,683.09% in one year.
| Current Share Class | 174.27M |
| Shares Outstanding | 174.27M |
| Shares Change (YoY) | +4,683.09% |
| Shares Change (QoQ) | +0.82% |
| Owned by Insiders (%) | 0.33% |
| Owned by Institutions (%) | 80.07% |
| Float | 138.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 742.39 |
| Forward PS | n/a |
| PB Ratio | 2.95 |
| P/TBV Ratio | 3.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 492.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.26
| Current Ratio | 24.26 |
| Quick Ratio | 23.96 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4,418.63 |
Financial Efficiency
Return on equity (ROE) is -51.37% and return on invested capital (ROIC) is -35.43%.
| Return on Equity (ROE) | -51.37% |
| Return on Assets (ROA) | -32.98% |
| Return on Invested Capital (ROIC) | -35.43% |
| Return on Capital Employed (ROCE) | -28.96% |
| Weighted Average Cost of Capital (WACC) | 12.71% |
| Revenue Per Employee | $35,714 |
| Profits Per Employee | -$2.28M |
| Employee Count | 14 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +207.88% in the last 52 weeks. The beta is 1.54, so Palisade Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.54 |
| 52-Week Price Change | +207.88% |
| 50-Day Moving Average | 2.00 |
| 200-Day Moving Average | 1.94 |
| Relative Strength Index (RSI) | 53.94 |
| Average Volume (20 Days) | 1,566,099 |
Short Selling Information
The latest short interest is 33.70 million, so 19.34% of the outstanding shares have been sold short.
| Short Interest | 33.70M |
| Short Previous Month | 37.02M |
| Short % of Shares Out | 19.34% |
| Short % of Float | 24.27% |
| Short Ratio (days to cover) | 10.91 |
Income Statement
In the last 12 months, Palisade Bio had revenue of $500,000 and -$31.94 million in losses. Loss per share was -$0.20.
| Revenue | 500,000 |
| Gross Profit | 500,000 |
| Operating Income | -35.35M |
| Pretax Income | -31.94M |
| Net Income | -31.94M |
| EBITDA | -35.35M |
| EBIT | -35.35M |
| Loss Per Share | -$0.20 |
Balance Sheet
The company has $125.17 million in cash and no debt, with a net cash position of $125.17 million or $0.72 per share.
| Cash & Cash Equivalents | 125.17M |
| Total Debt | n/a |
| Net Cash | 125.17M |
| Net Cash Per Share | $0.72 |
| Equity (Book Value) | 121.75M |
| Book Value Per Share | 0.70 |
| Working Capital | 122.01M |
Cash Flow
| Operating Cash Flow | -18.19M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2,500 |
| Net Borrowing | -311,000 |
| Free Cash Flow | -18.19M |
| FCF Per Share | -$0.10 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -7,069.80% |
| Pretax Margin | -6,388.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Palisade Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4,683.09% |
| Shareholder Yield | -4,683.09% |
| Earnings Yield | -8.60% |
| FCF Yield | -4.90% |
Analyst Forecast
The average price target for Palisade Bio is $10.22, which is 379.81% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.22 |
| Price Target Difference | 379.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 8, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | Apr 8, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
Palisade Bio has an Altman Z-Score of 21.8 and a Piotroski F-Score of 2.
| Altman Z-Score | 21.8 |
| Piotroski F-Score | 2 |